Bristol-Myers Squibb Company (FRA:BRM)
40.49
+0.66 (1.67%)
At close: Aug 13, 2025, 10:00 PM CET
FRA:BRM Revenue
Bristol-Myers Squibb Company had revenue of $12.27B USD in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
2.05
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
83.14B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Rheinmetall AG | 10.67B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Bristol-Myers Squibb Company News
- 7 days ago - RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program - Benzinga
- 9 days ago - Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity - Seeking Alpha
- 9 days ago - Bristol Myers gets priority review for Breyanzi's label expansion - Seeking Alpha
- 9 days ago - Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Wallstreet:Online
- 9 days ago - Procurement leaders talk about how AI changing the way they plan, report, and solve problems - Business Insider
- 10 days ago - Bristol-Myers Squibb: Buy The Weakness - Seeking Alpha
- 12 days ago - Bristol-Myers Squibb: Declines Have Gone Too Far - Seeking Alpha
- 12 days ago - Bristol Myers (BMY) Q2 EPS Jumps 36% - The Motley Fool